DAVID G JOHNSON to Polymorphism, Single Nucleotide
This is a "connection" page, showing publications DAVID G JOHNSON has written about Polymorphism, Single Nucleotide.
Connection Strength
0.974
-
Genetic factors underlying the risk of thalidomide-related neuropathy in patients with multiple myeloma. J Clin Oncol. 2011 Mar 01; 29(7):797-804.
Score: 0.167
-
Genetic associations with thalidomide mediated venous thrombotic events in myeloma identified using targeted genotyping. Blood. 2008 Dec 15; 112(13):4924-34.
Score: 0.142
-
Identification of multiple risk loci and regulatory mechanisms influencing susceptibility to multiple myeloma. Nat Commun. 2018 09 13; 9(1):3707.
Score: 0.071
-
Genetic Predisposition to Multiple Myeloma at 5q15 Is Mediated by an ELL2 Enhancer Polymorphism. Cell Rep. 2017 Sep 12; 20(11):2556-2564.
Score: 0.066
-
Genome-wide association study identifies variation at 6q25.1 associated with survival in multiple myeloma. Nat Commun. 2016 Jan 08; 7:10290.
Score: 0.059
-
Implementation of genome-wide complex trait analysis to quantify the heritability in multiple myeloma. Sci Rep. 2015 Jul 24; 5:12473.
Score: 0.057
-
FAAH genetic variation enhances fronto-amygdala function in mouse and human. Nat Commun. 2015 Mar 03; 6:6395.
Score: 0.056
-
The CCND1 c.870G>A polymorphism is a risk factor for t(11;14)(q13;q32) multiple myeloma. Nat Genet. 2013 May; 45(5):522-525.
Score: 0.049
-
Genetic factors underlying the risk of bortezomib induced peripheral neuropathy in multiple myeloma patients. Haematologica. 2011 Nov; 96(11):1728-32.
Score: 0.043
-
Effects of MDM2 promoter polymorphisms and p53 codon 72 polymorphism on risk and age at onset of squamous cell carcinoma of the head and neck. Mol Carcinog. 2011 Sep; 50(9):697-706.
Score: 0.043
-
Integration of global SNP-based mapping and expression arrays reveals key regions, mechanisms, and genes important in the pathogenesis of multiple myeloma. Blood. 2006 Sep 01; 108(5):1733-43.
Score: 0.030
-
Transcriptome-wide association study of multiple myeloma identifies candidate susceptibility genes. Hum Genomics. 2019 08 20; 13(1):37.
Score: 0.019
-
Regions of homozygosity as risk factors for multiple myeloma. Ann Hum Genet. 2019 07; 83(4):231-238.
Score: 0.018
-
Genetic correlation between multiple myeloma and chronic lymphocytic leukaemia provides evidence for shared aetiology. Blood Cancer J. 2018 12 21; 9(1):1.
Score: 0.018
-
Search for rare protein altering variants influencing susceptibility to multiple myeloma. Oncotarget. 2017 May 30; 8(22):36203-36210.
Score: 0.016
-
Genome-wide association analysis of chronic lymphocytic leukaemia, Hodgkin lymphoma and multiple myeloma identifies pleiotropic risk loci. Sci Rep. 2017 01 23; 7:41071.
Score: 0.016
-
Multiple myeloma risk variant at 7p15.3 creates an IRF4-binding site and interferes with CDCA7L expression. Nat Commun. 2016 11 24; 7:13656.
Score: 0.016
-
The 7p15.3 (rs4487645) association for multiple myeloma shows strong allele-specific regulation of the MYC-interacting gene CDCA7L in malignant plasma cells. Haematologica. 2015 Mar; 100(3):e110-3.
Score: 0.014
-
Inherited genetic susceptibility to monoclonal gammopathy of unknown significance. Blood. 2014 Apr 17; 123(16):2513-7; quiz 2593.
Score: 0.013
-
Common variation at 3p22.1 and 7p15.3 influences multiple myeloma risk. Nat Genet. 2011 Nov 27; 44(1):58-61.
Score: 0.011
-
Reductions in claudin-1 may enhance susceptibility to herpes simplex virus 1 infections in atopic dermatitis. J Allergy Clin Immunol. 2011 Jul; 128(1):242-246.e5.
Score: 0.011
-
A high-frequency regulatory polymorphism in the p53 pathway accelerates tumor development. Cancer Cell. 2010 Sep 14; 18(3):220-30.
Score: 0.010
-
A compendium of myeloma-associated chromosomal copy number abnormalities and their prognostic value. Blood. 2010 Oct 14; 116(15):e56-65.
Score: 0.010
-
Homozygous deletion mapping in myeloma samples identifies genes and an expression signature relevant to pathogenesis and outcome. Clin Cancer Res. 2010 Mar 15; 16(6):1856-64.
Score: 0.010
-
Enhanced skin carcinogenesis and lack of thymus hyperplasia in transgenic mice expressing human cyclin D1b (CCND1b). Mol Carcinog. 2009 Jun; 48(6):508-16.
Score: 0.009